2022 Fall Benefit Keynote – Dr. Dale Bredesen

Dr. Dale Bredesen
Professor, UCLA
CSO, Apollo Health
Author of the New York Times Bestseller The End of Alzheimer’s

Dr. Dale Bredesen‘s research on neurodegenerative diseases, especially Alzheimer’s, has laid the groundwork for the multi-therapeutic approach that has transformed how these diseases are diagnosed and treated. Dr. Bredesen’s laboratory studied basic mechanisms underlying the neurodegenerative process and how these might translate into effective therapeutics for Alzheimer’s disease, leading to the publication of over 220 research papers. He established the Alzheimer’s Drug Development Network with Dr. Varghese John, in which new classes of therapeutics for Alzheimer’s disease were identified. His work also led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with Mild Cognitive Impairment (MCI) and Alzheimer’s disease.

He has published two best-selling books about this approach: The End of Alzheimer’s and its companion, The End of Alzheimer’s Program. His most recent book describes case studies from the original successful proof-of-concept trial and subsequent clinical outcomes.

Dr. Bredesen graduated from Caltech and received his MD from Duke. He served as Resident and Chief Resident in Neurology at UCSF, then postdoctoral fellow with Nobel laureate Prof. Stanley Prusiner.  He was the Founding President of the Buck Institute for Research on Aging and is currently a professor at UCLA.